Background: Recently, newer generation drug-eluting stents (DESs) have been widely used with improved performance and safety. However, there have been limited data comparing angiographic and clinical outcomes of individual newer generation DESs in real world clinical practice, specifically in Asian population. Methods: A total of 608 patients (pts) underwent percutaneous coronary intervention (PCI) with Zotarolimus-eluting stents (ZES group; Endeavor ResoluteTM, n=238 pts) and Everolimus-eluting stents (EES group; PromusTM or XienceTM n=370 pts) were enrolled for this study. Angiographic outcomes at 6 months and major clinical outcomes up to 12 months were compared. Results: There were no significant differences in baseline clinical characteristics between the two groups. At 6 months, angiographic outcomes were similar between the two groups. At 12 months, there was a trend toward higher incidence of non-target lesion revascularization (TLR) target vessel revascularization (TVR) in the EES group; however other major clinical outcomes including mortality, Q-wave myocardial infarction (MI), repeat PCI and major adverse cardiac events (MACEs) were similar between the two groups up to 12 months (Table) Conclusions: In our study, both new generation DESs, ZES and EES were similarly effective and safe up to 1 year following routine PCI in Asian population